Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD, is a clinical-stage biopharmaceutical company operating in the immunotherapy sector that reached the public markets through a SPAC business combination. The company filed an 8-K current report with the SEC on August 18, 2023, under accession number 0001213900-23-069046, disclosing a material corporate event to investors. Estrella's pipeline focuses on immune-oncology and autoimmune indications, placing it within the healthcare and life sciences segment that has drawn consistent SPAC sponsor interest in recent years. The filing reflects the ongoing regulatory and disclosure obligations that follow a completed de-SPAC transaction. Sign up at SpacDesk for full filing history, deal timeline, and sponsor data on UPTD and hundreds of other SPAC transactions.